Literature DB >> 11686476

Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations.

S Yamada1, M Onda, S Kato, N Matsuda, T Matsuhisa, N Yamada, M Miki, N Matsukura.   

Abstract

BACKGROUND: This study was designed to compare genetic differences in single-nucleotide polymorphisms of the S-mephenytoin 4'-hydroxylation (CYP2C19) gene among four Asian populations.
METHODS: Polymerase chain reaction with restriction fragment length polymorphism (PCR-RFLP) analysis of CYP2C19 was conducted in Japanese, Chinese, Thai, and Vietnamese populations. All genotype frequencies were analyzed. Wild-type homozygote and wild-type heterozygote genotypes were extensive proton pump inhibitor (PPI) metabolizers. Mutant-type heterozygote and mutant-type homozygote genotypes were poor PPI metabolizers.
RESULTS: No significant differences in CYP2C19 phenotype, calculated based on genotype frequencies, (P > 0.05) were found among the four populations.
CONCLUSIONS: Many factors, including CYP2C19 polymorphisms, affect the success rate of Helicobacterpylori eradication with PPI-based therapy. We suspect that CYP2C19 polymorphisms may not be the main factor associated with differences among these four Asian populations in the success rates of H. pylori eradication with PPI-based therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686476     DOI: 10.1007/s005350170029

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  16 in total

1.  Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.

Authors:  Yipeng Ding; Dongchuan Xu; Xiyang Zhang; Hua Yang; Tingting Geng; Ping He; Jinjian Yao; Shengyang Yi; Heping Xu; Duoyi Wu; Xiang Wang; Tianbo Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.

Authors:  Yoshikazu Kinoshita; Shunji Ishihara
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

3.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

4.  Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.

Authors:  Nicole G Hunfeld; Ron A Mathot; Daan J Touw; Ron H van Schaik; Paul G Mulder; Paul F Franck; Ernst J Kuipers; William P Geus
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

5.  Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).

Authors:  K Pachkoria; M I Lucena; F Ruiz-Cabello; E Crespo; M R Cabello; R J Andrade
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

6.  Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.

Authors:  Jorge Vicente; Fabricio González-Andrade; Antonia Soriano; Ana Fanlo; Begoña Martínez-Jarreta; Blanca Sinués
Journal:  Mol Biol Rep       Date:  2014-01-16       Impact factor: 2.316

7.  Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.

Authors:  Heydy V Bravo-Villalta; Koujirou Yamamoto; Katsunori Nakamura; Ana Bayá; Yuko Okada; Ryuya Horiuchi
Journal:  Eur J Clin Pharmacol       Date:  2005-03-18       Impact factor: 2.953

8.  Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.

Authors:  Robabeh Ghiyas Tabari; Abdoljalal Marjani; Ogholdondy Agh Ataby; Azad Reza Mansourian; Nader Mansour Samai
Journal:  Oman Med J       Date:  2013-07

9.  Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.

Authors:  Jen-Kuang Lee; Cho-Kai Wu; Jyh-Ming Juang; Chia-Ti Tsai; Juey-Jen Hwang; Jiuun-Lee Lin; Fu-Tien Chiang
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

10.  Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.

Authors:  Tao Jiang; Zhengxing Rong; Yiping Xu; Bing Chen; Yifan Xie; Congying Chen; Yang Lu; Yifeng Shen; Huafang Li; Jing Sun; Hongzhuan Chen
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.